{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,24]],"date-time":"2026-04-24T18:37:43Z","timestamp":1777055863099,"version":"3.51.4"},"reference-count":47,"publisher":"Walter de Gruyter GmbH","issue":"1","funder":[{"DOI":"10.13039\/501100001659","name":"Deutsche Forschungsgemeinschaft","doi-asserted-by":"crossref","award":["GO 3055\/1-1, HO 1875\/24-1, 26-1, and 27-1, RA 2151\/4-1 and 5-1"],"award-info":[{"award-number":["GO 3055\/1-1, HO 1875\/24-1, 26-1, and 27-1, RA 2151\/4-1 and 5-1"]}],"id":[{"id":"10.13039\/501100001659","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100005972","name":"Deutsche Krebshilfe","doi-asserted-by":"crossref","award":["70113573 and as part of the Mildred-Scheel Nachwuchszentrum"],"award-info":[{"award-number":["70113573 and as part of the Mildred-Scheel Nachwuchszentrum"]}],"id":[{"id":"10.13039\/501100005972","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2022,1,26]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec id=\"j_cclm-2021-0504_abs_001\">\n                  <jats:title>Objectives<\/jats:title>\n                  <jats:p>Dickkopf-1 (DKK1) is a secreted protein, known for suppressing the differentiation and activity of bone-building osteoblasts by acting as an inhibitor of Wnt-signalling. Soluble DKK1 (sDKK1) has been proposed as prognostic biomarker for a wide range of malignancies, however, clinical relevance of sDKK1 as potential blood-based marker for ovarian cancer is unknown.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec id=\"j_cclm-2021-0504_abs_002\">\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>sDKK1 levels were quantified in a cohort of 150 clinically documented ovarian cancer patients by a commercially available DKK1 ELISA (Biomedica, Vienna, Austria).<\/jats:p>\n               <\/jats:sec>\n               <jats:sec id=\"j_cclm-2021-0504_abs_003\">\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>Median sDKK1 level was significantly elevated at primary diagnosis of ovarian cancer compared to healthy controls (estimated difference (ED) of 7.75\u00a0ng\/mL (95% CI: 3.01\u201312.30\u00a0ng\/mL, p=0.001)). Higher levels of sDKK1 at diagnosis indicated an increased volume of intraoperative malignant ascites (ED 7.08\u00a0pmol\/L, 95% CI: 1.46\u201313.05, p=0.02) and predicted suboptimal debulking surgery (ED 6.88\u00a0pmol\/L, 95% CI: 1.73\u201311.87, p=0.01). sDKK1 did not correlate with CA125 and higher sDKK1 levels predicted a higher risk of recurrence and poor survival (PFS: HR=0.507, 95% CI: 0.317\u20130.809; p=0.004; OS: HR=0.561, 95% CI: 0.320\u20130.986; p=0.044). Prognostic relevance of sDKK1 was partly sustained in wt<jats:italic>BRCA<\/jats:italic> patients (PFS: HR=0.507, 95% CI: 0.317\u20130.809; p=0.004).<\/jats:p>\n               <\/jats:sec>\n               <jats:sec id=\"j_cclm-2021-0504_abs_004\">\n                  <jats:title>Conclusions<\/jats:title>\n                  <jats:p>This is the first study demonstrating the prognostic relevance of sDKK1 in ovarian cancer patients, including those with wt<jats:italic>BRCA<\/jats:italic>\n                     <jats:italic>1\/2<\/jats:italic> status. Our data encourage further evaluation of sDKK1 in ovarian cancer patients, possibly in terms of a therapy monitoring marker or a response predictor for sDKK1-directed targeted therapies.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1515\/cclm-2021-0504","type":"journal-article","created":{"date-parts":[[2021,10,23]],"date-time":"2021-10-23T20:49:57Z","timestamp":1635022197000},"page":"109-117","source":"Crossref","is-referenced-by-count":7,"title":["Evaluation of circulating Dickkopf-1 as a prognostic biomarker in ovarian cancer patients"],"prefix":"10.1515","volume":"60","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7696-9043","authenticated-orcid":false,"given":"Daniel Martin","family":"Klotz","sequence":"first","affiliation":[{"name":"Department of Gynecology and Obstetrics, Medical Faculty and University Hospital Carl Gustav Carus, Technische Universit\u00e4t Dresden , Dresden , Germany"},{"name":"German Cancer Consortium (DKTK), partner site Dresden and German Cancer Research Center (DKFZ) , Heidelberg , Germany"},{"name":"National Center for Tumor Diseases (NCT), Dresden, Germany: German Cancer Research Center (DKFZ) , Heidelberg , Germany"},{"name":"Faculty of Medicine and University Hospital Carl Gustav Carus, Technische Universit\u00e4t Dresden , Dresden , Germany"},{"name":"Helmholtz-Zentrum Dresden - Rossendorf (HZDR) , Dresden , Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Theresa","family":"Link","sequence":"additional","affiliation":[{"name":"Department of Gynecology and Obstetrics, Medical Faculty and University Hospital Carl Gustav Carus, Technische Universit\u00e4t Dresden , Dresden , Germany"},{"name":"German Cancer Consortium (DKTK), partner site Dresden and German Cancer Research Center (DKFZ) , Heidelberg , Germany"},{"name":"National Center for Tumor Diseases (NCT), Dresden, Germany: German Cancer Research Center (DKFZ) , Heidelberg , Germany"},{"name":"Faculty of Medicine and University Hospital Carl Gustav Carus, Technische Universit\u00e4t Dresden , Dresden , Germany"},{"name":"Helmholtz-Zentrum Dresden - Rossendorf (HZDR) , Dresden , Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maren","family":"Goeckenjan","sequence":"additional","affiliation":[{"name":"Department of Gynecology and Obstetrics, Medical Faculty and University Hospital Carl Gustav Carus, Technische Universit\u00e4t Dresden , Dresden , Germany"},{"name":"German Cancer Consortium (DKTK), partner site Dresden and German Cancer Research Center (DKFZ) , Heidelberg , Germany"},{"name":"National Center for Tumor Diseases (NCT), Dresden, Germany: German Cancer Research Center (DKFZ) , Heidelberg , Germany"},{"name":"Faculty of Medicine and University Hospital Carl Gustav Carus, Technische Universit\u00e4t Dresden , Dresden , Germany"},{"name":"Helmholtz-Zentrum Dresden - Rossendorf (HZDR) , Dresden , Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pauline","family":"Wimberger","sequence":"additional","affiliation":[{"name":"Department of Gynecology and Obstetrics, Medical Faculty and University Hospital Carl Gustav Carus, Technische Universit\u00e4t Dresden , Dresden , Germany"},{"name":"German Cancer Consortium (DKTK), partner site Dresden and German Cancer Research Center (DKFZ) , Heidelberg , Germany"},{"name":"National Center for Tumor Diseases (NCT), Dresden, Germany: German Cancer Research Center (DKFZ) , Heidelberg , Germany"},{"name":"Faculty of Medicine and University Hospital Carl Gustav Carus, Technische Universit\u00e4t Dresden , Dresden , Germany"},{"name":"Helmholtz-Zentrum Dresden - Rossendorf (HZDR) , Dresden , Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anna R.","family":"Poetsch","sequence":"additional","affiliation":[{"name":"Biotechnology Center, Technische Universit\u00e4t Dresden , Dresden , Germany"},{"name":"German Cancer Consortium (DKTK), partner site Dresden and German Cancer Research Center (DKFZ) , Heidelberg , Germany"},{"name":"National Center for Tumor Diseases (NCT), Dresden, Germany: German Cancer Research Center (DKFZ) , Heidelberg , Germany"},{"name":"Faculty of Medicine and University Hospital Carl Gustav Carus, Technische Universit\u00e4t Dresden , Dresden , Germany"},{"name":"Helmholtz-Zentrum Dresden - Rossendorf (HZDR) , Dresden , Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nikolai","family":"Jaschke","sequence":"additional","affiliation":[{"name":"Division of Endocrinology, Diabetes, and Bone Diseases, Department of Medicine III, Technische Universit\u00e4t Dresden ; Dresden , Germany"},{"name":"German Cancer Consortium (DKTK), partner site Dresden and German Cancer Research Center (DKFZ) , Heidelberg , Germany"},{"name":"National Center for Tumor Diseases (NCT), Dresden, Germany: German Cancer Research Center (DKFZ) , Heidelberg , Germany"},{"name":"Faculty of Medicine and University Hospital Carl Gustav Carus, Technische Universit\u00e4t Dresden , Dresden , Germany"},{"name":"Helmholtz-Zentrum Dresden - Rossendorf (HZDR) , Dresden , Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lorenz C.","family":"Hofbauer","sequence":"additional","affiliation":[{"name":"Division of Endocrinology, Diabetes, and Bone Diseases, Department of Medicine III, Technische Universit\u00e4t Dresden ; Dresden , Germany"},{"name":"German Cancer Consortium (DKTK), partner site Dresden and German Cancer Research Center (DKFZ) , Heidelberg , Germany"},{"name":"National Center for Tumor Diseases (NCT), Dresden, Germany: German Cancer Research Center (DKFZ) , Heidelberg , Germany"},{"name":"Faculty of Medicine and University Hospital Carl Gustav Carus, Technische Universit\u00e4t Dresden , Dresden , Germany"},{"name":"Helmholtz-Zentrum Dresden - Rossendorf (HZDR) , Dresden , Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andy","family":"G\u00f6bel","sequence":"additional","affiliation":[{"name":"Division of Endocrinology, Diabetes, and Bone Diseases, Department of Medicine III, Technische Universit\u00e4t Dresden ; Dresden , Germany"},{"name":"German Cancer Consortium (DKTK), partner site Dresden and German Cancer Research Center (DKFZ) , Heidelberg , Germany"},{"name":"National Center for Tumor Diseases (NCT), Dresden, Germany: German Cancer Research Center (DKFZ) , Heidelberg , Germany"},{"name":"Faculty of Medicine and University Hospital Carl Gustav Carus, Technische Universit\u00e4t Dresden , Dresden , Germany"},{"name":"Helmholtz-Zentrum Dresden - Rossendorf (HZDR) , Dresden , Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tilman D.","family":"Rachner","sequence":"additional","affiliation":[{"name":"Division of Endocrinology, Diabetes, and Bone Diseases, Department of Medicine III, Technische Universit\u00e4t Dresden ; Dresden , Germany"},{"name":"German Cancer Consortium (DKTK), partner site Dresden and German Cancer Research Center (DKFZ) , Heidelberg , Germany"},{"name":"National Center for Tumor Diseases (NCT), Dresden, Germany: German Cancer Research Center (DKFZ) , Heidelberg , Germany"},{"name":"Faculty of Medicine and University Hospital Carl Gustav Carus, Technische Universit\u00e4t Dresden , Dresden , Germany"},{"name":"Helmholtz-Zentrum Dresden - Rossendorf (HZDR) , Dresden , Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3820-3017","authenticated-orcid":false,"given":"Jan Dominik","family":"Kuhlmann","sequence":"additional","affiliation":[{"name":"Department of Gynecology and Obstetrics, Medical Faculty and University Hospital Carl Gustav Carus, Technische Universit\u00e4t Dresden , Dresden , Germany"},{"name":"German Cancer Consortium (DKTK), partner site Dresden and German Cancer Research Center (DKFZ) , Heidelberg , Germany"},{"name":"National Center for Tumor Diseases (NCT), Dresden, Germany: German Cancer Research Center (DKFZ) , Heidelberg , Germany"},{"name":"Faculty of Medicine and University Hospital Carl Gustav Carus, Technische Universit\u00e4t Dresden , Dresden , Germany"},{"name":"Helmholtz-Zentrum Dresden - Rossendorf (HZDR) , Dresden , Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"374","published-online":{"date-parts":[[2021,10,25]]},"reference":[{"key":"2023033114225876390_j_cclm-2021-0504_ref_001","doi-asserted-by":"crossref","unstructured":"Torre, LA, Trabert, B, DeSantis, CE, Miller, KD, Samimi, G, Runowicz, CD, et al.. Ovarian cancer statistics. CA Cancer J Clin 2018;68:284\u201396. https:\/\/doi.org\/10.3322\/caac.21456.","DOI":"10.3322\/caac.21456"},{"key":"2023033114225876390_j_cclm-2021-0504_ref_002","doi-asserted-by":"crossref","unstructured":"Buys, SS, Partridge, E, Greene, MH, Prorok, PC, Reding, D, Riley, TL, et al.. Ovarian cancer screening in the prostate, lung, colorectal and ovarian (PLCO) cancer screening trial: findings from the initial screen of a randomized trial. Am J Obstet Gynecol 2005;193:1630\u20139. https:\/\/doi.org\/10.1016\/j.ajog.2005.05.005.","DOI":"10.1016\/j.ajog.2005.05.005"},{"key":"2023033114225876390_j_cclm-2021-0504_ref_003","doi-asserted-by":"crossref","unstructured":"du Bois, A, Quinn, M, Thigpen, T, Vermorken, J, Avall-Lundqvist, E, Bookman, M, et al.. 2004 consensus statements on the management of ovarian cancer: final document of the 3rd International Gynecologic Cancer Intergroup Ovarian Cancer Consensus Conference (GCIG OCCC 2004). Ann Oncol 2005;16:viii7\u201312. https:\/\/doi.org\/10.1093\/annonc\/mdi961.","DOI":"10.1093\/annonc\/mdi961"},{"key":"2023033114225876390_j_cclm-2021-0504_ref_004","doi-asserted-by":"crossref","unstructured":"Karam, A, Ledermann, JA, Kim, J-W, Sehouli, J, Lu, K, Gourley, C, et al.. Fifth Ovarian Cancer Consensus Conference of the Gynecologic Cancer InterGroup: first-line interventions. Ann Oncol 2017;28:711\u20137. https:\/\/doi.org\/10.1093\/annonc\/mdx011.","DOI":"10.1093\/annonc\/mdx011"},{"key":"2023033114225876390_j_cclm-2021-0504_ref_005","doi-asserted-by":"crossref","unstructured":"Stuart, GCE, Kitchener, H, Bacon, M, DuBois, A, Friedlander, M, Ledermann, J, et al.. 2010 Gynecologic Cancer InterGroup (GCIG) consensus statement on clinical trials in ovarian cancer: report from the Fourth Ovarian Cancer Consensus Conference. Int J Gynecol Cancer 2011;21:750\u20135. https:\/\/doi.org\/10.1097\/igc.0b013e31821b2568.","DOI":"10.1097\/IGC.0b013e31821b2568"},{"key":"2023033114225876390_j_cclm-2021-0504_ref_006","doi-asserted-by":"crossref","unstructured":"Burger, RA, Brady, MF, Bookman, MA, Fleming, GF, Monk, BJ, Huang, H, et al.. Incorporation of bevacizumab in the primary treatment of ovarian cancer. N Engl J Med 2011;365:2473\u201383. https:\/\/doi.org\/10.1056\/nejmoa1104390.","DOI":"10.1056\/NEJMoa1104390"},{"key":"2023033114225876390_j_cclm-2021-0504_ref_007","doi-asserted-by":"crossref","unstructured":"Ray-Coquard, I, Pautier, P, Pignata, S, P\u00e9rol, D, Gonz\u00e1lez-Mart\u00edn, A, Berger, R, et al.. Olaparib plus bevacizumab as first-line maintenance in ovarian cancer. N Engl J Med 2019;381:2416\u201328. https:\/\/doi.org\/10.1056\/nejmoa1911361.","DOI":"10.1056\/NEJMoa1911361"},{"key":"2023033114225876390_j_cclm-2021-0504_ref_008","doi-asserted-by":"crossref","unstructured":"Gonz\u00e1lez-Mart\u00edn, A, Pothuri, B, Vergote, I, DePont Christensen, R, Graybill, W, Mirza, MR, et al.. Niraparib in patients with newly diagnosed advanced ovarian cancer. N Engl J Med 2019;381:2391\u2013402. https:\/\/doi.org\/10.1056\/nejmoa1910962.","DOI":"10.1056\/NEJMoa1910962"},{"key":"2023033114225876390_j_cclm-2021-0504_ref_009","doi-asserted-by":"crossref","unstructured":"Wimberger, P, Wehling, M, Lehmann, N, Kimmig, R, Schmalfeldt, B, Burges, A, et al.. Influence of residual tumor on outcome in ovarian cancer patients with FIGO stage IV disease. Ann Surg Oncol 2010;17:1642\u20138. https:\/\/doi.org\/10.1245\/s10434-010-0964-9.","DOI":"10.1245\/s10434-010-0964-9"},{"key":"2023033114225876390_j_cclm-2021-0504_ref_010","doi-asserted-by":"crossref","unstructured":"Moore, K, Colombo, N, Scambia, G, Kim, BG, Oaknin, A, Friedlander, M, et al.. Maintenance olaparib in patients with newly diagnosed advanced ovarian cancer. N Engl J Med 2018;379:2495\u2013505. https:\/\/doi.org\/10.1056\/nejmoa1810858.","DOI":"10.1056\/NEJMoa1810858"},{"key":"2023033114225876390_j_cclm-2021-0504_ref_011","doi-asserted-by":"crossref","unstructured":"Klotz, DM, Wimberger, P. Overcoming PARP inhibitor resistance in ovarian cancer: what are the most promising strategies? Arch Gynecol Obstet 2020;302:1087\u2013102. https:\/\/doi.org\/10.1007\/s00404-020-05677-1.","DOI":"10.1007\/s00404-020-05677-1"},{"key":"2023033114225876390_j_cclm-2021-0504_ref_012","doi-asserted-by":"crossref","unstructured":"Oliveira, L, Horvat, N, Andrieu, PIC, Panizza, PSB, Cerri, GG, Viana, PCC. Ovarian cancer staging: what the surgeon needs to know. Br J Radiol 2021;94:20210091. https:\/\/doi.org\/10.1259\/bjr.20210091.","DOI":"10.1259\/bjr.20210091"},{"key":"2023033114225876390_j_cclm-2021-0504_ref_013","doi-asserted-by":"crossref","unstructured":"Glinka, A, Wu, W, Delius, H, Monaghan, AP, Blumenstock, C, Niehrs, C. Dickkopf-1 is a member of a new family of secreted proteins and functions in head induction. Nature 1998;391:357\u201362. https:\/\/doi.org\/10.1038\/34848.","DOI":"10.1038\/34848"},{"key":"2023033114225876390_j_cclm-2021-0504_ref_014","doi-asserted-by":"crossref","unstructured":"Baron, R, Kneissel, M. WNT signaling in bone homeostasis and disease\u202f: from human mutations to treatments. Nat Med 2013;19:179\u201392. https:\/\/doi.org\/10.1038\/nm.3074.","DOI":"10.1038\/nm.3074"},{"key":"2023033114225876390_j_cclm-2021-0504_ref_015","doi-asserted-by":"crossref","unstructured":"Tian, E, Zhan, F, Walker, R, Rasmussen, E, Ma, Y, Barlogie, B, et al.. The role of the Wnt-signalling antagonist DKK1 in the development of osteolytic lesions in multiple myeloma. N Engl J Med 2003;349:2438\u201394. https:\/\/doi.org\/10.1056\/NEJMoa030847.","DOI":"10.1056\/NEJMoa030847"},{"key":"2023033114225876390_j_cclm-2021-0504_ref_016","doi-asserted-by":"crossref","unstructured":"Hall, CL, Daignault, SD, Shah, RB, Pienta, KJ, Keller, ET. Dickkopf-1 expression increases early in prostate cancer development and decreases during progression from primary tumor to metastasis. Prostate 2008;68:1396\u2013404. https:\/\/doi.org\/10.1002\/pros.20805.","DOI":"10.1002\/pros.20805"},{"key":"2023033114225876390_j_cclm-2021-0504_ref_017","doi-asserted-by":"crossref","unstructured":"Qin, W, Xu, W-H, Shao, Z-M, Yang, C, Liu, Z-B. Expression of Dickkopf-1 and beta-catenin related to the prognosis of breast cancer patients with triple negative phenotype. PLoS One 2012;7:e37624. https:\/\/doi.org\/10.1371\/journal.pone.0037624.","DOI":"10.1371\/journal.pone.0037624"},{"key":"2023033114225876390_j_cclm-2021-0504_ref_018","doi-asserted-by":"crossref","unstructured":"Voorzanger-Rousselot, N, Goehrig, D, Journe, F, Doriath, V, Body, JJ, Cl\u00e9zardin, P, et al.. Increased Dickkopf-1 expression in breast cancer bone metastases. Br J Cancer 2007;97:964\u201370. https:\/\/doi.org\/10.1038\/sj.bjc.6603959.","DOI":"10.1038\/sj.bjc.6603959"},{"key":"2023033114225876390_j_cclm-2021-0504_ref_019","doi-asserted-by":"crossref","unstructured":"Voorzanger-Rousselot, N, Journe, F, Doriath, V, Body, JJ, Garnero, P. Assessment of circulating Dickkopf-1 with a new two-site immunoassay in healthy subjects and women with breast cancer and bone metastases. Calcif Tissue Int 2009;84:348\u201354. https:\/\/doi.org\/10.1007\/s00223-009-9225-y.","DOI":"10.1007\/s00223-009-9225-y"},{"key":"2023033114225876390_j_cclm-2021-0504_ref_020","doi-asserted-by":"crossref","unstructured":"Jaschke, N, Hofbauer, LC, G\u00f6bel, A, Rachner, TD. Evolving functions of Dickkopf-1 in cancer and immunity. Cancer Lett 2020;482:1\u20137. https:\/\/doi.org\/10.1016\/j.canlet.2020.03.031.","DOI":"10.1016\/j.canlet.2020.03.031"},{"key":"2023033114225876390_j_cclm-2021-0504_ref_021","doi-asserted-by":"crossref","unstructured":"Choi, SH, Kim, H, Lee, HG, Kim, BK, Park, JY, Kim, DY, et al.. Dickkopf-1 induces angiogenesis via VEGF receptor 2 regulation independent of the Wnt signaling pathway. Oncotarget 2017;8:58974\u201384. https:\/\/doi.org\/10.18632\/oncotarget.19769.","DOI":"10.18632\/oncotarget.19769"},{"key":"2023033114225876390_j_cclm-2021-0504_ref_022","doi-asserted-by":"crossref","unstructured":"Krause, U, Ryan, DM, Clough, BH, Gregory, CA. An unexpected role for a Wnt-inhibitor: Dickkopf-1 triggers a novel cancer survival mechanism through modulation of aldehyde-dehydrogenase-1 activity. Cell Death Dis 2014;5:e1093. https:\/\/doi.org\/10.1038\/cddis.2014.67.","DOI":"10.1038\/cddis.2014.67"},{"key":"2023033114225876390_j_cclm-2021-0504_ref_023","doi-asserted-by":"crossref","unstructured":"Hall, CL, Zhang, H, Baile, S, Ljungman, M, Kuhstoss, S, Keller, ET. p21CIP-1\/WAF-1 induction is required to inhibit prostate cancer growth elicited by deficient expression of the Wnt inhibitor Dickkopf-1. Cancer Res 2010;70:9916\u201326. https:\/\/doi.org\/10.1158\/0008-5472.can-10-0440.","DOI":"10.1158\/0008-5472.CAN-10-0440"},{"key":"2023033114225876390_j_cclm-2021-0504_ref_024","doi-asserted-by":"crossref","unstructured":"Haas, MS, Kagey, MH, Heath, H, Schuerpf, F, Newman, W, Rottman, JB. mDKN-01, a novel anti-DKK1 monoclonal antibody, enhances innate immune responses in the tumor microenvironment. Mol Cancer Res 2020;19:717\u201325. https:\/\/doi.org\/10.1158\/1541-7786.MCR-20-0799.","DOI":"10.1158\/1541-7786.MCR-20-0799"},{"key":"2023033114225876390_j_cclm-2021-0504_ref_025","doi-asserted-by":"crossref","unstructured":"Goldstein, SD, Trucco, M, Guzman, WB, Hayashi, M, Loeb, DM. A monoclonal antibody against the Wnt signaling inhibitor Dickkopf-1 inhibits osteosarcoma metastasis in a preclinical model. Oncotarget 2016;7:21114\u201323. https:\/\/doi.org\/10.18632\/oncotarget.8522.","DOI":"10.18632\/oncotarget.8522"},{"key":"2023033114225876390_j_cclm-2021-0504_ref_026","doi-asserted-by":"crossref","unstructured":"Huang, J, Lu, T, Kuang, W. Prognostic role of Dickkopf-1 in patients with cancer. Medicine (Baltim) 2020;99:e20388. https:\/\/doi.org\/10.1097\/md.0000000000020388.","DOI":"10.1097\/MD.0000000000020388"},{"key":"2023033114225876390_j_cclm-2021-0504_ref_027","doi-asserted-by":"crossref","unstructured":"Zhou, SJ, Zhuo, SR, Yang, XQ, Qin, CX, Wang, ZL. Serum Dickkopf-1 expression level positively correlates with a poor prognosis in breast cancer. Diagn Pathol 2014;9:161\u20134. https:\/\/doi.org\/10.1186\/s13000-014-0161-4.","DOI":"10.1186\/s13000-014-0161-4"},{"key":"2023033114225876390_j_cclm-2021-0504_ref_028","doi-asserted-by":"crossref","unstructured":"Rachner, TD, Thiele, S, G\u00f6bel, A, Browne, A, Fuessel, S, Erdmann, K, et al.. High serum levels of Dickkopf-1 are associated with a poor prognosis in prostate cancer patients. BMC Cancer 2014;14:649. https:\/\/doi.org\/10.1186\/1471-2407-14-649.","DOI":"10.1186\/1471-2407-14-649"},{"key":"2023033114225876390_j_cclm-2021-0504_ref_029","doi-asserted-by":"crossref","unstructured":"Kaiser, M, Mieth, M, Liebisch, P, Oberl\u00e4nder, R, Rademacher, J, Jakob, C, et al.. Serum concentrations of DKK-1 correlate with the extent of bone disease in patients with multiple myeloma. Eur J Haematol 2008;80:490\u20134. https:\/\/doi.org\/10.1111\/j.1600-0609.2008.01065.x.","DOI":"10.1111\/j.1600-0609.2008.01065.x"},{"key":"2023033114225876390_j_cclm-2021-0504_ref_030","doi-asserted-by":"crossref","unstructured":"Heath, DJ, Chantry, AD, Buckle, CH, Coulton, L, Shaughnessy, JD, Evans, HR, et al.. Inhibiting Dickkopf-1 (Dkkl) removes suppression of bone formation and prevents the development of osteolytic bone disease in multiple myeloma. J Bone Miner Res 2009;24:425\u201336. https:\/\/doi.org\/10.1359\/jbmr.081104.","DOI":"10.1359\/jbmr.081104"},{"key":"2023033114225876390_j_cclm-2021-0504_ref_031","doi-asserted-by":"crossref","unstructured":"Fulciniti, M, Tassone, P, Hideshima, T, Vallet, S, Nanjappa, P, Ettenberg, SA, et al.. Anti-DKK1 mAb (BHQ880) as a potential therapeutic agent for multiple myeloma. Blood 2009;114:371\u20139. https:\/\/doi.org\/10.1182\/blood-2008-11-191577.","DOI":"10.1182\/blood-2008-11-191577"},{"key":"2023033114225876390_j_cclm-2021-0504_ref_032","doi-asserted-by":"crossref","unstructured":"Zhang, C, Guo, X, Peltzer, K, Ma, W, Qi, L, Zhang, Y, et al.. The prevalence, associated factors for bone metastases development and prognosis in newly diagnosed ovarian cancer: a large population based real-world study. J Cancer 2019;10:3133\u20139. https:\/\/doi.org\/10.7150\/jca.30335.","DOI":"10.7150\/jca.30335"},{"key":"2023033114225876390_j_cclm-2021-0504_ref_033","doi-asserted-by":"crossref","unstructured":"FIGO Committee on Gynecologic Oncology. Current FIGO staging for cancer of the vagina, fallopian tube, ovary, and gestational trophoblastic neoplasia. Int J Gynecol Obstet 2009;105:3\u20134. https:\/\/doi.org\/10.1016\/j.ijgo.2008.12.015.","DOI":"10.1016\/j.ijgo.2008.12.015"},{"key":"2023033114225876390_j_cclm-2021-0504_ref_034","doi-asserted-by":"crossref","unstructured":"Prat, J, FIGO Committee on Gynecologic Oncology. Staging classification for cancer of the ovary, fallopian tube, and peritoneum. Int J Gynecol Obstet 2014;124:1\u20135. https:\/\/doi.org\/10.1016\/j.ijgo.2013.10.001.","DOI":"10.1016\/j.ijgo.2013.10.001"},{"key":"2023033114225876390_j_cclm-2021-0504_ref_035","doi-asserted-by":"crossref","unstructured":"Harter, P, Hauke, J, Heitz, F, Reuss, A, Kommoss, S, Marm\u00e9, F, et al.. Prevalence of deleterious germline variants in risk genes including BRCA1\/2 in consecutive ovarian cancer patients (AGO-TR-1). Galli A, editor. PLoS One 2017;12:e0186043. https:\/\/doi.org\/10.1371\/journal.pone.0186043.","DOI":"10.1371\/journal.pone.0186043"},{"key":"2023033114225876390_j_cclm-2021-0504_ref_036","doi-asserted-by":"crossref","unstructured":"Kast, K, Rhiem, K, Wappenschmidt, B, Hahnen, E, Hauke, J, Bluemcke, B, et al.. Prevalence of BRCA1\/2 germline mutations in 21 401 families with breast and ovarian cancer. J Med Genet 2016;53:465\u201371. https:\/\/doi.org\/10.1136\/jmedgenet-2015-103672.","DOI":"10.1136\/jmedgenet-2015-103672"},{"key":"2023033114225876390_j_cclm-2021-0504_ref_037","doi-asserted-by":"crossref","unstructured":"Link, T, Passek, S, Wimberger, P, Frank, K, Vassileva, YD, Kramer, M, et al.. Serum calretinin as an independent predictor for platinum resistance and prognosis in ovarian cancer. Int J Cancer 2020;146:2608\u201318. https:\/\/doi.org\/10.1002\/ijc.32676.","DOI":"10.1002\/ijc.32676"},{"key":"2023033114225876390_j_cclm-2021-0504_ref_038","doi-asserted-by":"crossref","unstructured":"Link, T, Kuhlmann, JD, Kobelt, D, Herrmann, P, Vassileva, YD, Kramer, M, et al.. Clinical relevance of circulating MACC1 and S100A4 transcripts for ovarian cancer. Mol Oncol 2019;13:1268\u201379. https:\/\/doi.org\/10.1002\/1878-0261.12484.","DOI":"10.1002\/1878-0261.12484"},{"key":"2023033114225876390_j_cclm-2021-0504_ref_039","doi-asserted-by":"crossref","unstructured":"Shizhuo, W, Tao, J, Shulan, Z, Bing, Z. The expression and significance of Dickkopf-1 in epithelial ovarian carcinoma. Int J Biol Markers 2009;24:165\u201370. https:\/\/doi.org\/10.1177\/172460080902400306.","DOI":"10.1177\/172460080902400306"},{"key":"2023033114225876390_j_cclm-2021-0504_ref_040","doi-asserted-by":"crossref","unstructured":"Wang, S, Zhang, S. Dickkopf-1 is frequently overexpressed in ovarian serous carcinoma and involved in tumor invasion. Clin Exp Metastasis 2011;28:581\u201391. https:\/\/doi.org\/10.1007\/s10585-011-9393-9.","DOI":"10.1007\/s10585-011-9393-9"},{"key":"2023033114225876390_j_cclm-2021-0504_ref_041","doi-asserted-by":"crossref","unstructured":"Zhang, R, Lin, HM, Broering, R, Shi, XD, Yu, XH, Xu, LB, et al.. Dickkopf-1 contributes to hepatocellular carcinoma tumorigenesis by activating the wnt\/\u03b2-catenin signaling pathway. Signal Transduct Targeted Ther 2019;4:1\u201310. https:\/\/doi.org\/10.1038\/s41392-019-0082-5.","DOI":"10.1038\/s41392-019-0082-5"},{"key":"2023033114225876390_j_cclm-2021-0504_ref_042","doi-asserted-by":"crossref","unstructured":"Zhu, G, Song, J, Chen, W, Yuan, D, Wang, W, Chen, X, et al.. Expression and role of Dickkopf-1 (Dkk1) in tumors: from the cells to the patients. Cancer Manag Res 2021;13:659\u201375. https:\/\/doi.org\/10.2147\/cmar.s275172.","DOI":"10.2147\/CMAR.S275172"},{"key":"2023033114225876390_j_cclm-2021-0504_ref_043","doi-asserted-by":"crossref","unstructured":"Rachner, TD, G\u00f6bel, A, Benad-Mehner, P, Hofbauer, LC, Rauner, M. Dickkopf-1 as a mediator and novel target in malignant bone disease. Cancer Lett 2014;346:172\u20137. https:\/\/doi.org\/10.1016\/j.canlet.2014.01.010.","DOI":"10.1016\/j.canlet.2014.01.010"},{"key":"2023033114225876390_j_cclm-2021-0504_ref_044","doi-asserted-by":"crossref","unstructured":"D\u2019Amico, L, Mahajan, S, Capietto, A-HH, Yang, Z, Zamani, A, Ricci, B, et al.. Dickkopf-related protein 1 (Dkk1) regulates the accumulation and function of myeloid derived suppressor cells in cancer. J Exp Med 2016;213:827\u201340. https:\/\/doi.org\/10.1084\/jem.20150950.","DOI":"10.1084\/jem.20150950"},{"key":"2023033114225876390_j_cclm-2021-0504_ref_045","doi-asserted-by":"crossref","unstructured":"Smadja, DM, d\u2019Audigier, C, Weiswald, LB, Badoual, C, Dangles-Marie, V, Mauge, L, et al.. The Wnt antagonist Dickkopf-1 increases endothelial progenitor cell angiogenic potential. Arterioscler Thromb Vasc Biol 2010;30:2544\u201352. https:\/\/doi.org\/10.1161\/atvbaha.110.213751.","DOI":"10.1161\/ATVBAHA.110.213751"},{"key":"2023033114225876390_j_cclm-2021-0504_ref_046","doi-asserted-by":"crossref","unstructured":"Baert, T, Vankerckhoven, A, Riva, M, Van Hoylandt, A, Thirion, G, Holger, G, et al.. Myeloid derived suppressor cells: key drivers of immunosuppression in ovarian cancer. Front Immunol 2019;10:1273. https:\/\/doi.org\/10.3389\/fimmu.2019.01273.","DOI":"10.3389\/fimmu.2019.01273"},{"key":"2023033114225876390_j_cclm-2021-0504_ref_047","doi-asserted-by":"crossref","unstructured":"Salim, H, Zong, D, Haag, P, Novak, M, Mork, B, Lewensohn, R, et al.. DKK1 is a potential novel mediator of cisplatin-refractoriness in non-small cell lung cancer cell lines. BMC Cancer 2015;15:628. https:\/\/doi.org\/10.1186\/s12885-015-1635-9.","DOI":"10.1186\/s12885-015-1635-9"}],"container-title":["Clinical Chemistry and Laboratory Medicine (CCLM)"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.degruyter.com\/document\/doi\/10.1515\/cclm-2021-0504\/xml","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.degruyter.com\/document\/doi\/10.1515\/cclm-2021-0504\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,3,31]],"date-time":"2023-03-31T20:44:08Z","timestamp":1680295448000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.degruyter.com\/document\/doi\/10.1515\/cclm-2021-0504\/html"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,10,25]]},"references-count":47,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2021,9,2]]},"published-print":{"date-parts":[[2022,1,26]]}},"alternative-id":["10.1515\/cclm-2021-0504"],"URL":"https:\/\/doi.org\/10.1515\/cclm-2021-0504","relation":{},"ISSN":["1434-6621","1437-4331"],"issn-type":[{"value":"1434-6621","type":"print"},{"value":"1437-4331","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,10,25]]}}}